Discovering new drugs with help from Darwinian principles

The way drugs work is based on the molecular recognition of a target protein involved in the disease, in order to disarm it. To do this, scientists use high-throughput screening to identify which molecule could become a drug, specifically targeting the protein of interest. Over the last ten years, the technique has been improved by encoding small molecules with DNA tags that simplify their identification, as DNA is easy to decode.

Drawing inspiration from Darwinian evolutionary forces to find efficient assemblies

Today, chemists at the UNIGE have gone one step further, drawing inspiration from Darwin's theories: "Biology always finds a solution to a problem, explains Nicolas Winssinger, professor in the Department of Organic Chemistry at the Faculty of Science, UNIGE, and the corresponding author of the study. This is the principle of natural evolution, which consists of amplifying the best individuals, while generating diversity to adapt and survive changing conditions. That's what we've set up for small molecules." Indeed, the scientists have developed a technology that generates diversity by creating more than 100 million assemblies of molecules via their DNA, which they then select to best match a particular protein.

"We were inspired by the characteristics of antibodies that recognise target proteins and sought to mimic them in the form of simpler molecules to allow them to be assembled in different combinations, directed by DNA sequences," explains Nicolas Winssinger. These combinations are then selected and amplified several times to find the best possible match with the protein to be targeted, all in one to two weeks, compared with months or even a year for traditional high-throughput screening.

A proven, easily reproducible and inexpensive technique

To validate the effectiveness of this methodology, the Geneva team focused on the PD-L1 protein, which protects cancer cells by diverting the immune system. "Thanks to our methodology, we quickly identified an assembly that specifically targets PD-L1, confirming that it works effectively," says Nicolas Winssinger.

This technique, which is easy to reproduce in any laboratory in the world, costs only a few thousand francs, compared with millions for high-throughput screening. "By exploiting the evolutionary forces highlighted by Darwin, we can now improve our molecular assemblies and open up a new space of possible combinations that has not yet been exploited, in order to create new, more effective drugs," concludes the Geneva researcher.